Radiotherapy-drug combinations in the treatment of glioblastoma: a brief review

McAleavey, P. G., Walls, G. M. and Chalmers, A. J. (2022) Radiotherapy-drug combinations in the treatment of glioblastoma: a brief review. CNS Oncology, 11(2), CNS86. (doi: 10.2217/cns-2021-0015) (PMID:35603818) (PMCID:PMC9134931)

[img] Text
271569.pdf - Published Version
Available under License Creative Commons Attribution.



Glioblastoma (GBM) accounts for over 50% of gliomas and carries the worst prognosis of all solid tumors. Owing to the limited local control afforded by surgery alone, efficacious adjuvant treatments such as radiotherapy (RT) and chemotherapy are fundamental in achieving durable disease control. The best clinical outcomes are achieved with tri-modality treatment consisting of surgery, RT and systemic therapy. While RT-chemotherapy combination regimens are well established in oncology, this approach was largely unsuccessful in GBM until the introduction of temozolomide. The success of this combination has stimulated the search for other candidate drugs for concomitant use with RT in GBM. This review seeks to collate the current evidence for these agents and synthesize possible future directions for the field.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Chalmers, Professor Anthony
Authors: McAleavey, P. G., Walls, G. M., and Chalmers, A. J.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:CNS Oncology
Publisher:Future Medicine
ISSN (Online):2045-0915
Published Online:23 May 2022
Copyright Holders:Copyright © 2022 Patrick G McAleavey
First Published:First published in CNS Oncology 11(2):CNS86
Publisher Policy:Reproduced under a Creative Commons license

University Staff: Request a correction | Enlighten Editors: Update this record